文献速递白血病

达沙替尼治疗慢性髓性白血病患者的肺部不良事件

[Dasatinib-related pulmonary adverse events in patients with chronic myeloid leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

该回顾性研究纳入280例接受达沙替尼治疗的CML患者,中位治疗26个月,胸腔积液发生率为32.1%,肺动脉高压高度可能性约占3.5%。年龄增加、进展期及心血管合并症与胸腔积液发生相关,进展期、确诊至TKI治疗≤6个月及发现胸腔积液时剂量<100 mg/d与积液程度更重相关。

要点

  • 达沙替尼治疗CML患者胸腔积液常见(32.1%),多为1-2级。
  • 肺动脉高压高度可能性约占3.5%,且为可逆性。
  • 年龄增加、进展期及心血管合并症增加胸腔积液风险。

核心结论

  • 胸腔积液是达沙替尼常见肺部不良事件,肺动脉高压较少见,应识别高危人群、密切监测和及时干预。

研究设计与样本

  • 回顾性分析2008年4月至2020年1月北京大学人民医院接受达沙替尼治疗的280例CML患者。
  • 中位达沙替尼治疗时间26(1-142)个月。

主要发现

  • 90例(32.1%)发生胸腔积液,其中1级40例(44.4%)、2级44例(48.9%)、3级6例(6.7%)。
  • 胸腔积液发生率随服药时间延长逐渐升高。
  • 60例有咳嗽、胸闷或气促症状的患者中,49例接受超声心动图检查,8例(16.3%)发现肺动脉高压高度可能性,约占所有患者的3.5%。
  • 8例肺动脉高压高度可能性患者中6例(75.0%)合并胸腔积液,肺动脉高压为可逆性。
  • 原研与国产达沙替尼的胸腔积液和肺动脉高压发生率差异无统计学意义(P>0.05)。

关键数值与推荐

  • 年龄增加(每增加10岁,HR=1.6,P<0.001)与胸腔积液发生显著相关。
  • 服用达沙替尼时处于进展期(HR=2.2,P=0.008)与胸腔积液发生显著相关。
  • 有心血管疾病合并症(HR=1.9,P=0.018)与胸腔积液发生显著相关。
  • 服用达沙替尼时处于进展期(HR=3.4,P=0.001)与胸腔积液程度更重相关。
  • 确诊至开始服用酪氨酸激酶抑制剂时间≤6个月(HR=2.2,P=0.015)与胸腔积液程度更重相关。

临床怎么用

  • 对年龄较大、进展期开始治疗或有心血管合并症的患者应密切监测胸腔积液。
  • 出现咳嗽、胸闷或气促症状时应行超声心动图筛查肺动脉高压。
  • 胸腔积液经减停达沙替尼、利尿、胸腔穿刺或置管等干预后,半数患者减少或消失;减量服用者绝大多数可维持原治疗反应。

局限性

  • 本研究为单中心回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore dasatinib-related pulmonary adverse events in patients with chronic myeloid leukemia (CML) . Methods: We retrospectively analyzed the incidence of pleural effusion (PE) and pulmonary arterial hypertension (PAH) in patients with CML treated with dasatinib at Peking University People's Hospital from April 2008 to January 2020. Results: A total of 280 patients were collected. The median dasatinib treatment time was 26 (1-142) months. Ninety (32.1%) patients developed PE, including 40 (44.4%) in grade 1, 44 (48.9%) in grade 2, and 6 (6.7%) in grade 3. The incidence of PE increased gradually with the prolongation of treatment. The multivariate analysis showed that increasing age (every 10 years, HR=1.6; P<0.001) , advanced phase when starting dasatinib therapy (HR=2.2; P=0.008) , and cardiovascular comorbidity (ies) (HR=1.9; P=0.018) were significantly associated with developing PE. The advanced phase when starting dasatinib therapy (HR=3.4; P=0.001) , interval from diagnosis to taking TKI for ≤6 months (HR=2.2; P=0.015) , and dose < 100 mg/d when PE was found (HR=3.1; P=0.001) were associated with more severe PE. PE relieved or disappeared after intervention in half of the patients. Among 60 patients with symptoms of cough, chest tightness, and shortness of breath, 49 underwent ultrasonic cardiography; 8 (16.3%) had high probability of PAH, approximately 3.5% in all patients; and 6 (75.0%) of them had PE. PAH was reversible. There was no difference in the incidences of PE and PAH between branded and Chinese generic dasatinib. Conclusion: PE is a common dasatinib-related pulmonary adverse event, and PAH is rare in patients with CML. The identification of individuals with high risk, close monitoring, and timely intervention may help to alleviate PE and PAH. 目的: 探索慢性髓性白血病(CML)患者接受达沙替尼治疗中肺部不良反应的发生率、影响因素及治疗转归。 方法: 回顾性分析2008年4月至2020年1月在北京大学人民医院接受达沙替尼治疗的CML患者胸腔积液(PE)和肺动脉高压(PAH)的发生情况。 结果: 共纳入280例患者,中位达沙替尼治疗时间26(1~142)个月,发现PE 90例(32.1%),其中1级40例(44.4%),2级44例(48.9%),3级6例(6.7%)。PE发生率随服药时间延长逐渐升高,多因素分析结果显示,年龄增加(每增加10岁,HR=1.6,P<0.001)、服用达沙替尼时处于进展期(HR=2.2,P=0.008)和有心血管疾病合并症(HR=1.9,P=0.018)与PE发生显著相关。服用达沙替尼时处于进展期(HR=3.4,P=0.001)、确诊至开始服用酪氨酸激酶抑制剂时间≤6个月(HR=2.2,P=0.015)、发现PE时剂量<100 mg/d(HR=3.1,P=0.001)者PE程度更重。经减停达沙替尼、利尿、胸腔穿刺或置管等干预,半数患者PE减少或消失。减量服用达沙替尼的患者中,绝大多数可维持原治疗反应。在有咳嗽、胸闷或气促等症状的60例患者中,49例接受超声心动图(UCG)检查,8例(16.3%)发现PAH高度可能性,约占所有患者中的3.5%,其中6例(75.0%)合并PE,PAH为可逆性。原研与国产达沙替尼的PE和PAH发生率差异无统计学意义(P>0.05)。 结论: 在服用达沙替尼的CML患者中,PE是常见的不良反应,PAH较少见,应注意识别高危人群、密切监测和及时干预。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yang S, Qin YZ, Lai YY, et al. [Dasatinib-related pulmonary adverse events in patients with chronic myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 33445849. doi:10.3760/cma.j.issn.0253-2727.2020.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。